NASDAQ
No price data available for this timeframe.
Karyopharm Therapeutics Inc. (KPTI) has a revenue compound annual growth rate of 6.21% over 5 years and 89.09% over 10 years. Revenue CAGR shows the compound annual growth rate of a company's total sales, indicating the pace of top-line expansion.